Please Scroll Down to See Forums Below smoknjilly
New member
Just curious, been reading all about it and wondered if the effects were different for females...
thanks!!@!
thanks!!@!
Any ladies here ever taken bromocriptine?
- Thread starter smoknjilly
- Start date
Punschkrapfen
New member
bromocriptine is clinically used for Hyperprolactinemia, Parkinson's Disease and Acromegaly. Lyle McDonald has written extensivly about the possible use of bromocriptine to aid weight loss.
Diabetes Care 1996 Jun;19(6):667-70 Related Articles, Books, LinkOut
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Cincotta AH, Meier AH.
Ergo Science, Charlestown, Massachusetts 02129, USA.
OBJECTIVE: A double-blind placebo controlled study investigated long-term effects of Ergoset, a new quick release formulation of bromocriptine, on body weight, body fat, and glucose tolerance in a group (n = 17) of obese subjects who were instructed to follow a moderate hypocaloric diet. RESEARCH DESIGN AND METHODS: Obese individuals (> 25% body fat for men and > 30% body fat for women) were instructed to follow a calorie-restricted diet (70% of weight maintaining based on study entry weight) and were randomized to daily treatment with Ergoset (1.6-2.4 mg/day) or placebo at 0800 over an 18-week treatment period. Oral glucose tolerance tests were performed on subjects before initiation and again at termination of treatment. Body weight and body fat (determined by skinfold measurements) were quantified every 2 weeks during the course of treatment. RESULTS: Ergoset treatment for 18 weeks significantly reduced body weight and body fat versus placebo (6.3 +/- 1.5 and 5.4 +/- 1.1 kg vs. 0.9 +/- 1.0 and 1.5 +/- 0.6 kg. respectively, P < 0.01). Ergoset, but not placebo, also improved glucose tolerance (P < 0.02); the stimulated area under the oral glucose tolerance curve was reduced by 46% (from 121 +/- 23 to 64 +/- 32 mg.h-1.dl-1), while the stimulated area under the insulin curve was reduced by 30%. CONCLUSIONS: When combined with instruction to follow a moderate hypocaloric diet, Ergoset, but not placebo, improves glucose tolerance and promotes significant weight and body fat loss in obese subjects over an 18- week treatment period.
Experientia 1992 Mar 15;48(3):248-53 Related Articles, Books, LinkOut
Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.
Meier AH, Cincotta AH, Lovell WC.
Dept. of Zoology and Physiology, Louisiana State University, Baton Rouge 70803.
Obese postmenopausal female volunteers were given timed daily oral dosages of bromocriptine, and tested for reduction of body fat stores. This dopamine agonist has been shown to reset circadian rhythms that are altered in obese animals and to reduce body fat levels in several animal models. The participants were instructed not to alter their existing exercise and eating behavior during treatment. Skinfold measurements were taken on 33 subjects as indices of body fat. The measurements (e.g., suprailiac) were reduced after six weeks by about 25%, which represents a reduction of 11.7% of the total body fat. These dramatic decreases in body fat, which are equivalent to that produced by severe caloric restriction, were accompanied by more modest reductions of body weight (2.5%), indicating a possible conservation of protein that is usually lost as a consequence of such caloric restriction. The effects of bromocriptine treatment on body fat and hyperglycemia were also examined in non-insulin dependent diabetics being treated with oral hypoglycemics (7 subjects) or insulin (7 subjects). Total body fat was reduced by 10.7% and 5.1% in diabetics on oral hypoglycemics and insulin, respectively, without any significant reductions in body weight. Hyperglycemia was reduced in most of the 15 diabetic subjects treated leading to euglycemia and even cessation of hypoglycemic drugs in 3 of the 7 subjects during 4-8 weeks of bromocriptine treatment. These findings support the hypothesis that obesity and type II diabetes may be treated effectively with bromocriptine when administered at the proper times and dosages.
problem is, what works in post-menopausal women does not neccessary work pre menopause. The first study was sponsored by the manufacturer, so it might be overstating the results.
If anyone is interested i can upload 9MB of Lyle McDonalds' writings about bromocriptine.
Diabetes Care 1996 Jun;19(6):667-70 Related Articles, Books, LinkOut
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Cincotta AH, Meier AH.
Ergo Science, Charlestown, Massachusetts 02129, USA.
OBJECTIVE: A double-blind placebo controlled study investigated long-term effects of Ergoset, a new quick release formulation of bromocriptine, on body weight, body fat, and glucose tolerance in a group (n = 17) of obese subjects who were instructed to follow a moderate hypocaloric diet. RESEARCH DESIGN AND METHODS: Obese individuals (> 25% body fat for men and > 30% body fat for women) were instructed to follow a calorie-restricted diet (70% of weight maintaining based on study entry weight) and were randomized to daily treatment with Ergoset (1.6-2.4 mg/day) or placebo at 0800 over an 18-week treatment period. Oral glucose tolerance tests were performed on subjects before initiation and again at termination of treatment. Body weight and body fat (determined by skinfold measurements) were quantified every 2 weeks during the course of treatment. RESULTS: Ergoset treatment for 18 weeks significantly reduced body weight and body fat versus placebo (6.3 +/- 1.5 and 5.4 +/- 1.1 kg vs. 0.9 +/- 1.0 and 1.5 +/- 0.6 kg. respectively, P < 0.01). Ergoset, but not placebo, also improved glucose tolerance (P < 0.02); the stimulated area under the oral glucose tolerance curve was reduced by 46% (from 121 +/- 23 to 64 +/- 32 mg.h-1.dl-1), while the stimulated area under the insulin curve was reduced by 30%. CONCLUSIONS: When combined with instruction to follow a moderate hypocaloric diet, Ergoset, but not placebo, improves glucose tolerance and promotes significant weight and body fat loss in obese subjects over an 18- week treatment period.
Experientia 1992 Mar 15;48(3):248-53 Related Articles, Books, LinkOut
Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.
Meier AH, Cincotta AH, Lovell WC.
Dept. of Zoology and Physiology, Louisiana State University, Baton Rouge 70803.
Obese postmenopausal female volunteers were given timed daily oral dosages of bromocriptine, and tested for reduction of body fat stores. This dopamine agonist has been shown to reset circadian rhythms that are altered in obese animals and to reduce body fat levels in several animal models. The participants were instructed not to alter their existing exercise and eating behavior during treatment. Skinfold measurements were taken on 33 subjects as indices of body fat. The measurements (e.g., suprailiac) were reduced after six weeks by about 25%, which represents a reduction of 11.7% of the total body fat. These dramatic decreases in body fat, which are equivalent to that produced by severe caloric restriction, were accompanied by more modest reductions of body weight (2.5%), indicating a possible conservation of protein that is usually lost as a consequence of such caloric restriction. The effects of bromocriptine treatment on body fat and hyperglycemia were also examined in non-insulin dependent diabetics being treated with oral hypoglycemics (7 subjects) or insulin (7 subjects). Total body fat was reduced by 10.7% and 5.1% in diabetics on oral hypoglycemics and insulin, respectively, without any significant reductions in body weight. Hyperglycemia was reduced in most of the 15 diabetic subjects treated leading to euglycemia and even cessation of hypoglycemic drugs in 3 of the 7 subjects during 4-8 weeks of bromocriptine treatment. These findings support the hypothesis that obesity and type II diabetes may be treated effectively with bromocriptine when administered at the proper times and dosages.
problem is, what works in post-menopausal women does not neccessary work pre menopause. The first study was sponsored by the manufacturer, so it might be overstating the results.
If anyone is interested i can upload 9MB of Lyle McDonalds' writings about bromocriptine.
Just so you realize that it's not a perfectly innocuous drug to be taking, and that if you DO decide to try it, please have you BP monitored and stop if you feel unwell (headaches etc...):
"Symptomatic hypotension can occur in patients treated with bromocriptine for any indication.
In postpartum studies with bromocriptine, decreases in supine systolic and diastolic
pressures of greater than 20 mm and 10 mm Hg, respectively, have been observed in almost 30% of
patients receiving bromocriptine. On occasion, the drop in supine systolic pressure was
as much as 50-59 mm of Hg. While hypotension during the start of therapy with bromocriptine
mesylate occurs in some patients, in postmarketing experience in the U.S. in postpartum patients
89 cases of hypertension have been reported, sometimes at the initiation of therapy, but often
developing in the second week of therapy; seizures have been reported in 72 cases (including 4 cases of
status epilepticus), both with and without the prior development of hypertension; 30 cases of
stroke have been reported mostly in postpartum patients whose prenatal and obstetric courses
had been uncomplicated. Many of these patients experiencing seizures and/or strokes reported developing
a constant and often progressively severe headache hours to days prior to the acute event. Some
cases of strokes and seizures were also preceded by visual disturbances (blurred vision, and
transient cortical blindness). Nine cases of acute myocardial infarction have been reported.
Although a causal relationship between bromocriptine mesylate administration and hypertension,
seizures, strokes, and myocardial infarction in post-partum women has not been established, use of
the drug for prevention of physiological lactation, or in patients with uncontrolled
hypertension is not recommended. In patients being treated for hyperprolactinemia
bromocriptine should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS,
Hyperprolactinemic States). In the event that bromocriptine is reinstituted to control a
rapidly expanding macroadenoma (see PRECAUTIONS, Hyperprolactinemic States) and a
patient experiences a hypertensive disorder of pregnancy, the benefit of continuing
bromocriptine must be weighed against the possible risk of its use during a hypertensive
disorder of pregnancy. When bromocriptine is being used to treat acromegaly or Parkinson’s
disease in patients who subsequently become pregnant, a decision should be made as to whether the
therapy continues to be medically necesssary or can be withdrawn. If it is continued, the drug should be
withdrawn in those who may experience hypertensive disorders of pregnancy (including
eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine
is considered to be medically contraindicated. Because of the possibility of an interaction
between bromocriptine and other ergot alkaloids, the concomitant use of these medications
is not recommended. Particular attention should be paid to patients who have recently received other
drugs that can alter the blood pressure. Periodic monitoring of the blood pressure, particularly during
the first weeks of therapy is prudent. If hypertension, severe, progressive, or unremitting headache
(with or without visual disturbance), or evidence of CNS toxicity develops, drug therapy should be
discontinued and the patient should be evaluated promptly.
Long-term treatment (6-36 months) with bromocriptine in doses ranging from 20-100
mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura
in a few patients. In those instances in which bromocriptine treatment was terminated, the
changes slowly reverted towards normal."
"Symptomatic hypotension can occur in patients treated with bromocriptine for any indication.
In postpartum studies with bromocriptine, decreases in supine systolic and diastolic
pressures of greater than 20 mm and 10 mm Hg, respectively, have been observed in almost 30% of
patients receiving bromocriptine. On occasion, the drop in supine systolic pressure was
as much as 50-59 mm of Hg. While hypotension during the start of therapy with bromocriptine
mesylate occurs in some patients, in postmarketing experience in the U.S. in postpartum patients
89 cases of hypertension have been reported, sometimes at the initiation of therapy, but often
developing in the second week of therapy; seizures have been reported in 72 cases (including 4 cases of
status epilepticus), both with and without the prior development of hypertension; 30 cases of
stroke have been reported mostly in postpartum patients whose prenatal and obstetric courses
had been uncomplicated. Many of these patients experiencing seizures and/or strokes reported developing
a constant and often progressively severe headache hours to days prior to the acute event. Some
cases of strokes and seizures were also preceded by visual disturbances (blurred vision, and
transient cortical blindness). Nine cases of acute myocardial infarction have been reported.
Although a causal relationship between bromocriptine mesylate administration and hypertension,
seizures, strokes, and myocardial infarction in post-partum women has not been established, use of
the drug for prevention of physiological lactation, or in patients with uncontrolled
hypertension is not recommended. In patients being treated for hyperprolactinemia
bromocriptine should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS,
Hyperprolactinemic States). In the event that bromocriptine is reinstituted to control a
rapidly expanding macroadenoma (see PRECAUTIONS, Hyperprolactinemic States) and a
patient experiences a hypertensive disorder of pregnancy, the benefit of continuing
bromocriptine must be weighed against the possible risk of its use during a hypertensive
disorder of pregnancy. When bromocriptine is being used to treat acromegaly or Parkinson’s
disease in patients who subsequently become pregnant, a decision should be made as to whether the
therapy continues to be medically necesssary or can be withdrawn. If it is continued, the drug should be
withdrawn in those who may experience hypertensive disorders of pregnancy (including
eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine
is considered to be medically contraindicated. Because of the possibility of an interaction
between bromocriptine and other ergot alkaloids, the concomitant use of these medications
is not recommended. Particular attention should be paid to patients who have recently received other
drugs that can alter the blood pressure. Periodic monitoring of the blood pressure, particularly during
the first weeks of therapy is prudent. If hypertension, severe, progressive, or unremitting headache
(with or without visual disturbance), or evidence of CNS toxicity develops, drug therapy should be
discontinued and the patient should be evaluated promptly.
Long-term treatment (6-36 months) with bromocriptine in doses ranging from 20-100
mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura
in a few patients. In those instances in which bromocriptine treatment was terminated, the
changes slowly reverted towards normal."
C
Citruscide
Guest
Check out my post on it... it is in some better terminology... easier to understand.
http://boards.elitefitness.com/forum/showthread.php?threadid=221967
C-ditty
http://boards.elitefitness.com/forum/showthread.php?threadid=221967
C-ditty
SuperWoman
New member
I've taken this drug in the past for fat loss. It had great appetitie suppresant effects on me, it did increase libido, increased my mood in a positive way (made me happier?), I slept excellent on it, very restful and refreshing sleep. The first week it did make me nauseated and I only took half a pill, 1.5mg I think it was. I eventually got up to 1.5 pills per day but the effects of it seemed to wear off in about a month to a month and a half.
I liked the drug and will go on it when I'm lean to help keep me there. It could have worked for fat loss but my life and diet were both a mess then so I can't really report on it's fat loss benefits.
Ciao,
SW
I liked the drug and will go on it when I'm lean to help keep me there. It could have worked for fat loss but my life and diet were both a mess then so I can't really report on it's fat loss benefits.
Ciao,
SW
O
oicu812 - chargeback
Guest
I took it for a few weeks and it gave me some killer headaches. So I quit and that's when I discovered cialis. I love that stuff... No bad sides at all for me... I take it everyday, and it helps tremendously.
Similar threads
